Replacement therapies in hemophilia A and B
Efficacy of extended half-life products

08.30

Real life data: real benefits. What have we achieved?
Pratima Chowdari (UK)

09.00

How to optimize the use of extended half-life products (PK analysis)
Alfonso Iorio (Canada)

Safety of replacement therapies (standard and novel) (part I)

09.30

Which bleeding phenotype can we expect in severe hemophilia A previously untreated patient treated with non replacement therapies?
Karen Fijn van Draat (The Netherlands)

10.00

How safety of novel anti-hemophilic drugs should be approached. Known and unknown adverse effects
Flora Peyvandi (Italy)

10.30

Are Fc – FVIII products less immunogenic? New clinical data?
Christoph Königs (Germany)

11.00

Break

Safety of replacement therapies (standard and novel) (part II)

11.30

Long-term side-effects of pegylated products: facts or fancies?
TBA

12.00

European pharmacovigilance of new products (with special emphasis on pegylated products)
Anneliese Hilger (EMA, Germany)

12.30

Immunogenicity of subcutaneous and intravenous drugs
David Lillicrap (Canada)

13.00

Bayer Lunch Satellite Symposium
TBA

14.00

Satellite Symposium (booked)
TBA

15.00

Satellite Lecture
TBA

15.30

Oral Communications

16.30

Break

17.00

Choice of assays for novel anti-hemophilic therapies
Armando Tripodi (Italy)

The role of von Willebrand factor in factor VIII immunogenicity

17.30

FVIII peptide presentation to the immune system by VWF modulation
Jan Voorberg (Netherlands)

18.00

High VWF affinity FVIII and immunogenicity
Peter Lenting (France)

18.30

Walking Poster Session